Investigate the Safety, Tolerability and Pharmacokinetics of FBL-MTX
Status:
Completed
Trial end date:
2021-10-19
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, randomized, double-blind, placebocontrolled,
single-ascending dose (SAD) phase 1 study to evaluate the safety, tolerability and
pharmacokinetics of FBL-MTX in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd